Fennec Pharmaceuticals
FENC
48 hedge funds and large institutions have $77.4M invested in Fennec Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
7% more funds holding
Funds holding: 45 → 48 (+3)
2% more capital inflows, than outflows
Capital inflows: $3.5M | Capital outflows: $3.43M
0.56% less ownership
Funds ownership: 50.77% → 50.22% (-0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.54M |
| 2 |
6CM
683 Capital Management
New York
|
+$966K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$278K |
| 4 |
United Services Automobile Association
San Antonio,
Texas
|
+$250K |
| 5 |
Meeder Asset Management
Dublin,
Ohio
|
+$83.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.61M |
| 2 |
JP Morgan Chase
New York
|
-$329K |
| 3 |
Cardinal Capital Management Inc (North Carolina)
Raleigh,
North Carolina
|
-$272K |
| 4 |
TIAA CREF Investment Management
New York
|
-$62.6K |
| 5 |
Goldman Sachs
New York
|
-$60.8K |
FENC Hedge Fund Activity: Q3 2018 in Review
48 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2018, worth a combined $77.4M — down 21% from $98.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FENC positions and 3 closed out — a net gain of 3 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Granahan Investment Management, adding an estimated $1.54M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $2.61M sold.
- 48 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2018, up from 45 in Q2 2018.
- Funds reported $77.4M of Fennec Pharmaceuticals stock for Q3 2018, down 21% quarter-over-quarter.
- 6 funds opened new Fennec Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +3 holders.
- The largest Fennec Pharmaceuticals buyer in Q3 2018 was Granahan Investment Management, an estimated $1.54M added.
- The largest Fennec Pharmaceuticals seller in Q3 2018 was Acuta Capital Partners, an estimated $2.61M sold.
Based on aggregated 13F filings for Q3 2018.